KR850006132A - Bromocriptine Composition - Google Patents

Bromocriptine Composition Download PDF

Info

Publication number
KR850006132A
KR850006132A KR1019850001271A KR850001271A KR850006132A KR 850006132 A KR850006132 A KR 850006132A KR 1019850001271 A KR1019850001271 A KR 1019850001271A KR 850001271 A KR850001271 A KR 850001271A KR 850006132 A KR850006132 A KR 850006132A
Authority
KR
South Korea
Prior art keywords
composition
bromocriptine
controlled release
weight ratio
swelling
Prior art date
Application number
KR1019850001271A
Other languages
Korean (ko)
Inventor
쥐게르(외 1) 오트마르
Original Assignee
진 크라메르, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 진 크라메르, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 진 크라메르, 한스 루돌프 하우스
Publication of KR850006132A publication Critical patent/KR850006132A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음No content

Description

브로모그립틴 조성물Bromogriptin Composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도, 제2도 및 제3도는 캡슐 A, B 및 C투여후 측정한 프로락틴 농도를 평균곡선 A,B,C로 나타낸 그래프.1, 2 and 3 are graphs showing the average concentrations of prolactin measured after administration of capsules A, B and C as curves A, B and C.

Claims (21)

브로모크립틴, 약학적으로 알맞은 친수성 팽윤물질, 약학적으로 알맞은 불활성 지방물질로 구성되는 경구투여용의 조절될 방출조성물.A controlled release composition for oral administration comprising bromocriptine, a pharmaceutically suitable hydrophilic swelling material, and a pharmaceutically suitable inert fat material. 제1항에 있어서, 단위 복용형태량 2-200mg의 브로모 크립틴을 함유하는 조성물.The composition of claim 1, which contains a unit dosage amount of 2-200 mg of bromo kryptin. 제2항에 있어서, 5mg의 브로모크립틴을 함유하는 조성물.The composition of claim 2 containing 5 mg of bromocriptine. 제2항에 있어서, 10mg의 브로모크립틴을 함유하는 조성물.The composition of claim 2 containing 10 mg of bromocriptine. 제1항 내지 제4항중 어느 한항에 있어서, 팽윤물질이 셀룰로오스 히드로콜로이드인 조성물.The composition of claim 1 wherein the swelling material is cellulose hydrocolloid. 제1항 내지 제5항중 어느 한항에 있어서, 팽윤물질이 히드록시프로필메틸셀룰로오스인 조성물.The composition according to any one of claims 1 to 5, wherein the swelling material is hydroxypropylmethylcellulose. 제1항내지 제6항중 어느 한항에 있어서, 팽윤물질에 대한 브로모크립틴의 중량비율이 1 : 10-1 ; 25인 조성물.The weight ratio of bromocriptine to swelling material according to any one of claims 1 to 6; 25 is a composition. 제1항내지 제7항중 어느 한항에 있어서, 브로모크립틴에 대한 팽윤물질의 중량비율이 1 : 16-1 : 35인 조성물.The composition according to any one of claims 1 to 7, wherein the weight ratio of swelling material to bromocriptine is 1: 16-1: 35. 제1항 내지 제8항중 어느 한항에 있어서, 지방물질이 30-90℃의 융해점을 갖는 소수성물질인 조성물.The composition of claim 1, wherein the fatty material is a hydrophobic material having a melting point of 30-90 ° C. 10. 제1항 내지 제9항중 어느 한항에 있어서, 지방물질의 융점이 45-65℃인 조성물.The composition of claim 1, wherein the melting point of the fatty substance is 45-65 ° C. 11. 제1항내지 제10항중 어느 한항에 있어서, 지방물질이 글리세라이드인 조성물.The composition of any one of claims 1 to 10, wherein the fatty substance is glycerides. 제11항에 있어서, 글리세라이드가 글리세롤 디트리할미토스테아레이트인 조성물.The composition of claim 11 wherein the glyceride is glycerol ditrihalmitostearate. 제1항 내지 제12항중 어느 한항에 있어서, 지방물질에 대한 브로모크립틴의 중량비율이 1 : 1-1 ; 10인 조성물.The weight ratio of bromocriptine to fatty substance is 1: 1-1; 10 composition. 제13항에 있어서, 중량비가 1 : 6-1 : 10인 조성물.The composition of claim 13, wherein the weight ratio is 1: 6-1: 10. 제1항 내지 제14항 중 어느 한항에 있어서, 팽윤제로서 히드록시프로필메틸셀룰로오스를 함유하고, 지방물질로서 글리세롤 디트리팔미토스테아레이트를 함유하는 조성물.The composition according to any one of claims 1 to 14, which contains hydroxypropylmethylcellulose as a swelling agent and glycerol ditripalmitostearate as a fatty substance. 제15항에 있어서, 약 1 : 22 : 8 또는 1 : 12 : 4의 중량비율로 브로모크립틴, 히드록시프로필메틸셀룰로오스 및 글리세롤 디트리팔미토스테아레이트를 함유하는 조성물.The composition of claim 15 containing bromocriptine, hydroxypropylmethylcellulose and glycerol ditripalmitostearate in a weight ratio of about 1: 22: 8 or 1: 12: 4. 브로모크립틴 친수성 팽윤물질과 지방물질을 혼합하여 구성되는 경구투여용으로 조절된 방출조성물을 제조하는 방법.A method of preparing a controlled release composition for oral administration comprising a mixture of a bromocriptine hydrophilic swelling substance and a fatty substance. 제1항에 있어서, 실시예들중 어느 하나에 대하여 기술한 바와 같은 조성물.The composition of claim 1 as described for any one of the embodiments. 시험관내의 방출실험에서의 0.1노르말농도 염산에서 측정한 바와같이 2.5시간내에 브로모크립틴 50중량%보다 덜 방출하는 브로모크립틴의 조절된 방출조성물.A controlled release composition of bromocriptine that releases less than 50% by weight bromocriptine in 2.5 hours as measured by 0.1 normal concentration hydrochloric acid in an in vitro release experiment. 제19항에 있어서, 8시간내에 65중량%보다 덜 방출하는 조절된 방출조성물.The controlled release composition of claim 19 which releases less than 65% by weight in 8 hours. 제19항 또는 제20항에 있어서, 24시간내에 적어도 80중량%를 방출하는 조절된 방출조성물.A controlled release composition according to claim 19 or 20 which releases at least 80% by weight in 24 hours. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019850001271A 1984-02-29 1985-02-28 Bromocriptine Composition KR850006132A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH84-05227 1984-02-29
CH522784 1984-02-29

Publications (1)

Publication Number Publication Date
KR850006132A true KR850006132A (en) 1985-10-02

Family

ID=69105499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850001271A KR850006132A (en) 1984-02-29 1985-02-28 Bromocriptine Composition

Country Status (1)

Country Link
KR (1) KR850006132A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100456933B1 (en) * 1999-12-17 2004-11-10 르 라보레또레 쎄르비에르 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100456933B1 (en) * 1999-12-17 2004-11-10 르 라보레또레 쎄르비에르 Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route

Similar Documents

Publication Publication Date Title
US5064650A (en) Controlled-release salt sensitive capsule for oral use and adhesive system
CA1203172A (en) Propylene glycol diester solutions of pge-type compounds
KR910000655B1 (en) Process for preparing type soft capsule
BE901359A (en) PHARMACEUTICAL COMPOSITION WITH CONTROLLED ABSORPTION.
ATE5125T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING SANGUINARIA AND GALANGAL FOR THE TREATMENT OF PERIODONTITIS AND TUMORS.
DE642785T1 (en) Heterodisperse hydrogel systems for the delayed release of insoluble drugs.
ATE42463T1 (en) POLYETHYLENE GLYCOL SOFT GELATIN CAPSULES AND PROCESS FOR THEIR MANUFACTURE.
ES403435A1 (en) Slow release pharmaceutical compositions
KR880001288A (en) Sustained-release pharmaceutical compositions in oral dosage form
ATE68967T1 (en) GELATIN CAPSULES AND PROCESS FOR THEIR MANUFACTURE.
GB938828A (en) Improvements in or relating to pharmaceutical capsules comprising radioactive materials
KR850000239A (en) Preparation and Encapsulation Method of Particles
KR890007743A (en) Slow Release Galenical Compositions of Pharmaceutically Acceptable Diltiazem
RU1829935C (en) Method for producing flunarizine-containing composition
ATE172112T1 (en) METHOD FOR PRODUCING A SUSTAINED-RELEASE PREPARATION CONTAINING DILTIAZEM IN A SINGLE DAILY DOSE
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR870007121A (en) Sustained-release pharmaceutical compositions
US5164195A (en) Method of oral delivery with an adherent controlled-release salt sensitive capsule
KR850006132A (en) Bromocriptine Composition
JPS5350316A (en) Drug composition for oral administration
KR850006136A (en) Etoposide Oral Dosage Form
KR890001559A (en) Pharmaceutical Compositions Containing Trapidil, Methods For Making And Related Therapeutic Uses
KR860000070A (en) Tumor growth inhibitory composition
DE3578577D1 (en) METHOD FOR PRODUCING SOFT GEL CAPSULES.
KR890001565A (en) Injectable drugs containing 3-benzoyloxy-1,3,5 (10) -estratriene-17- [4- (P-bis (2-chloroethyl) amino) phenyl) butanoyloxy] acetate as active ingredient

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL